Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.85 |
| ▸ | MMP3 | P08254 | 3/20 | 0.85 |
| ▸ | ADAMTS1 | Q9UHI8 | 3/20 | 0.85 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.85 |
| ▸ | MMP8 | P22894 | 2/20 | 0.85 |
| ▸ | MMP10 | P09238 | 1/20 | 0.85 |
| ▸ | MMP14 | P50281 | 1/20 | 0.85 |
| ▸ | MMP15 | P51511 | 1/20 | 0.85 |
| ▸ | ADAM17 | P78536 | 18/20 | 0.77 |
| ▸ | MMP7 | P09237 | 2/20 | 0.77 |
| ▸ | MMP13 | P45452 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597239 | 0.92 | ADAMTS4 (1.00) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 | |
| SCHEMBL6597486 | 0.92 | ADAMTS4 (1.00) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 | |
| SCHEMBL6595323 | 0.89 | ADAMTS4 (0.75) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 | |
| SCHEMBL6598028 | 0.89 | ADAMTS4 (0.82) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 | |
| SCHEMBL6597063 | 0.89 | ADAMTS4 (0.82) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 | |
| SCHEMBL6598039 | 0.89 | ADAMTS4 (0.82) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 | |
| SCHEMBL6596017 | 0.89 | ADAMTS4 (0.82) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 | |
| SCHEMBL6597075 | 0.88 | ADAM17 (0.84) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 | |
| SCHEMBL6595563 | 0.88 | ADAM17 (0.83) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 | |
| SCHEMBL6595739 | 0.88 | ADAM17 (0.83) | ADAMTS4MMP3ADAMTS1ADAMTS5MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | DUAN JINGWU (US) | 2004-04-15 | — | — | US | claimed |
| EP-1263756-B1 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-02-25 | — | — | EP | claimed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | claimed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | claimed |
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | DUAN JINGWU (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1263756-B1 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | TNF, XPNPEP1, MMP2 | ADAMTS4 68/4885MMP3 12/4885ADAMTS1 62/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | ADAMTS4 61/4885MMP3 7/4885ADAMTS1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.